

## Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruysen-Witrand *et al*

We would like to thank Ruysen-Witrand *et al* for their interest in our study<sup>1</sup> and their data from French patients with rheumatoid arthritis collected during the first wave of the COVID-19 pandemic through an online survey.<sup>2</sup> Despite the fact that up to 70% of medical consultations could not be performed as planned due to confinement, adherence to immunosuppressive medication was very high (>80%), confirming our findings in Switzerland. This is all the more remarkable, as confinement measures were more stringent in France than in Switzerland. The rapid switch from physical visits to remote ways of patient–physician interaction, as also documented in their analysis, most probably led to these encouraging results.

Adrian Ciurea ,<sup>1</sup> Axel Finckh <sup>2</sup>

<sup>1</sup>Rheumatology, University Hospital Zurich, Zurich, Switzerland

<sup>2</sup>Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland

**Correspondence to** Professor Adrian Ciurea, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; [adrian.ciurea@usz.ch](mailto:adrian.ciurea@usz.ch)

**Handling editor** Josef S Smolen

**Contributors** AC and AF wrote the manuscript and approved the final version.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** AC reports personal fees from AbbVie, Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis and Pfizer, outside the submitted work.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Ciurea A, Finckh A. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-219420

Received 4 November 2020

Accepted 5 November 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-219409>

*Ann Rheum Dis* 2020;**0**:1. doi:10.1136/annrheumdis-2020-219420

### ORCID iDs

Adrian Ciurea <http://orcid.org/0000-0002-7870-7132>

Axel Finckh <http://orcid.org/0000-0002-1210-4347>

### REFERENCES

- 1 Ciurea A, Papagiannoulis E, Bürki K, *et al*. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss clinical quality management cohort. *Ann Rheum Dis* 2020;22:annrheumdis-2020-218705.
- 2 Ruysen-Witrand A, Soubrier M, Basch A, *et al*. Correspondence on "Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort". *Ann Rheum Dis* 2020. doi:10.1136/annrheumdis-2020-219409.